Market Overview:
The global cancer immunotherapy market is expected to grow at a CAGR of 16.8% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing incidence of cancer, technological advancements in the field of cancer immunotherapy, and rising demand for targeted therapies. Based on type, the global cancer immunotherapy market is segmented into monoclonal antibodies, immune checkpoint inhibitors, immune system modulators, and cancer vaccines. Monoclonal antibodies are expected to account for the largest share of the market in 2018. This can be attributed to their high efficacy and safety profile compared with other types of therapies. Based on application, lung cancer is expected to account for the largest share of the market in 2018 owing to its high prevalence worldwide.
Product Definition:
Cancer Immunotherapy is the use of treatments that harness the body's own immune system to fight cancer. Immunotherapy can work in two ways: it can boost the natural defenses of healthy cells, or it can directly attack tumor cells. Some immunotherapies are designed to help the body recognize and destroy cancer cells, while others use substances made by the body or lab-made molecules to boost or restore immune system function.
Monoclonal Antibodies:
Monoclonal antibodies are antibody molecules, which are manufactured by the human body specifically targeting cancer cells. These antibodies can attach to any part of the cell and kill it. Monoclonal Antibodies have various applications in oncology such as treatment of cancer, melanoma skin disease & autoimmune diseases like rheumatoid arthritis & lupus.
Immune Checkpoint Inhibitors:
Immune checkpoint inhibitors are a type of immunotherapy that works by decreasing the ability of cancer cells to evade immune detection. There are two types of immune checkpoints, namely inhibitory and stimulatory. The main function of an immune checkpoint is to modulate T-cell activity so that they attack only when it is necessary and help in minimizing collateral damage to non-cancerous cells.
The three major types include PD-1, CTLA-4,.
Application Insights:
The lung cancer segment dominated the market in 2017 owing to the availability of approved products for the treatment of Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). The approval of these products has been based on tumor response after 2 cycles of chemotherapy.
Immune checkpoint inhibitors are expected to witness lucrative growth over the forecast period due to their ability to treat advanced stages of various cancers, such as melanoma, renal cell carcinoma, bladder cancer, and head & neck cancer. Moreover, these drugs show potential as a panacea for several other types of cancers that have not yet been treated with any available therapy options. This is projected to provide a major impetus towards market growth during the forecast period.
Rising prevalence rates and awareness about immunotherapy treatments are anticipated drive revenue in other applications including prostate cancer.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, high R&D investment by companies, and availability of effective reimbursement policies for cancer immunotherapy treatments. Moreover, an increase in awareness about these therapies is also expected to drive growth during the forecast period. Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing disposable income levels and rising healthcare expenditure levels in emerging countries such as China and India. Furthermore, growing investments by major pharmaceutical companies for developing novel drugs are expected to boost demand across this region during the forecast period (2017-2030). In addition, favorable government initiatives pertaining political instability along with economic development are factors that have contributed significantly towards regional growth (For instance; Government Of India’s Swasthya Surakshit Matritva Abhiyan (SUSMA) scheme covers 80% cost of treatment under Cancer Special Scheme launched in 2012.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the global cancer immunotherapy market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This high incidence rate is expected to drive demand for novel and innovative therapies such as cancer immunotherapy drugs over the forecast period.
- Rising awareness about benefits of cancer immunotherapy: There has been a rising awareness about the benefits of using various forms of cancer immunotherapy among patients and healthcare professionals across the globe in recent years. This has led to an increase in adoption rates for these therapies, thereby driving market growth during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cancer Immunotherapy Market Research Report
By Type
Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines
By Application
Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Others
By Companies
Amgen, AstraZeneca, Roche, Bayer, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
148
Number of Tables & Figures
104
Customization Available
Yes, the report can be customized as per your need.
Global Cancer Immunotherapy Market Report Segments:
The global Cancer Immunotherapy market is segmented on the basis of:
Types
Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- AstraZeneca
- Roche
- Bayer
- Bristol-Myers Squibb
- Eli Lilly
- Merck
- Novartis
- Pfizer
Highlights of The Cancer Immunotherapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Immune Checkpoint Inhibitors
- Immune System Modulators
- Cancer Vaccines
- By Application:
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cancer Immunotherapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cancer immunotherapy is a type of cancer treatment that uses the bodyu2019s immune system to fight cancer. Cancer immunotherapy can be divided into two main types: adoptive cell therapy and checkpoint blockade.
Some of the major players in the cancer immunotherapy market are Amgen, AstraZeneca, Roche, Bayer, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer.
The cancer immunotherapy market is expected to register a CAGR of 16.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cancer Immunotherapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cancer Immunotherapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cancer Immunotherapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cancer Immunotherapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cancer Immunotherapy Market Size & Forecast, 2018-2028
4.5.1 Cancer Immunotherapy Market Size and Y-o-Y Growth
4.5.2 Cancer Immunotherapy Market Absolute $ Opportunity
Chapter 5 Global Cancer Immunotherapy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cancer Immunotherapy Market Size Forecast by Type
5.2.1 Monoclonal Antibodies
5.2.2 Immune Checkpoint Inhibitors
5.2.3 Immune System Modulators
5.2.4 Cancer Vaccines
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cancer Immunotherapy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cancer Immunotherapy Market Size Forecast by Applications
6.2.1 Lung Cancer
6.2.2 Breast Cancer
6.2.3 Colorectal Cancer
6.2.4 Melanoma
6.2.5 Prostate Cancer
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cancer Immunotherapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cancer Immunotherapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cancer Immunotherapy Analysis and Forecast
9.1 Introduction
9.2 North America Cancer Immunotherapy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cancer Immunotherapy Market Size Forecast by Type
9.6.1 Monoclonal Antibodies
9.6.2 Immune Checkpoint Inhibitors
9.6.3 Immune System Modulators
9.6.4 Cancer Vaccines
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cancer Immunotherapy Market Size Forecast by Applications
9.10.1 Lung Cancer
9.10.2 Breast Cancer
9.10.3 Colorectal Cancer
9.10.4 Melanoma
9.10.5 Prostate Cancer
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cancer Immunotherapy Analysis and Forecast
10.1 Introduction
10.2 Europe Cancer Immunotherapy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cancer Immunotherapy Market Size Forecast by Type
10.6.1 Monoclonal Antibodies
10.6.2 Immune Checkpoint Inhibitors
10.6.3 Immune System Modulators
10.6.4 Cancer Vaccines
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cancer Immunotherapy Market Size Forecast by Applications
10.10.1 Lung Cancer
10.10.2 Breast Cancer
10.10.3 Colorectal Cancer
10.10.4 Melanoma
10.10.5 Prostate Cancer
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cancer Immunotherapy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cancer Immunotherapy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cancer Immunotherapy Market Size Forecast by Type
11.6.1 Monoclonal Antibodies
11.6.2 Immune Checkpoint Inhibitors
11.6.3 Immune System Modulators
11.6.4 Cancer Vaccines
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cancer Immunotherapy Market Size Forecast by Applications
11.10.1 Lung Cancer
11.10.2 Breast Cancer
11.10.3 Colorectal Cancer
11.10.4 Melanoma
11.10.5 Prostate Cancer
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cancer Immunotherapy Analysis and Forecast
12.1 Introduction
12.2 Latin America Cancer Immunotherapy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cancer Immunotherapy Market Size Forecast by Type
12.6.1 Monoclonal Antibodies
12.6.2 Immune Checkpoint Inhibitors
12.6.3 Immune System Modulators
12.6.4 Cancer Vaccines
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cancer Immunotherapy Market Size Forecast by Applications
12.10.1 Lung Cancer
12.10.2 Breast Cancer
12.10.3 Colorectal Cancer
12.10.4 Melanoma
12.10.5 Prostate Cancer
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cancer Immunotherapy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cancer Immunotherapy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cancer Immunotherapy Market Size Forecast by Type
13.6.1 Monoclonal Antibodies
13.6.2 Immune Checkpoint Inhibitors
13.6.3 Immune System Modulators
13.6.4 Cancer Vaccines
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cancer Immunotherapy Market Size Forecast by Applications
13.10.1 Lung Cancer
13.10.2 Breast Cancer
13.10.3 Colorectal Cancer
13.10.4 Melanoma
13.10.5 Prostate Cancer
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cancer Immunotherapy Market: Competitive Dashboard
14.2 Global Cancer Immunotherapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 AstraZeneca
14.3.3 Roche
14.3.4 Bayer
14.3.5 Bristol-Myers Squibb
14.3.6 Eli Lilly
14.3.7 Merck
14.3.8 Novartis
14.3.9 Pfizer
